ArticleCancer treatment and research communications2026
KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.
Article in Cancer treatment and research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GenoGlyph: Pan-cancer genomic mutation inference and risk stratification from diagnostic histopathology slides.Research square · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundThe oral KRAS G12C inhibitors, sotorasib and adagrasib, were approved for advanced non-small cell lung cancer (NSCLC) in the later-line setting in 2021 and 2022, respectively. However, data are still emerging regarding how clinical and molecular variables impact outcomes.
methodsPatients with advanced KRAS G12C-mutant NSCLC who were treated at a matrix cancer center with an oral KRAS G12C inhibitor between May 2021 and August 2024 had their clinical and outcome data collected and analyzed.
resultsA total of 38 patients who met the inclusion criteria were identified. The overall median progression-free survival (PFS) of the cohort was 3.5 (95% confidence interval (CI) 2.7-6.1) months, and median overall survival (OS), 7.8 (4.8-11.0) months. Patients with a never or light smoking history (defined by a cutoff of ≤10 pack-years), worse Eastern Cooperative Oncology Group (ECOG) performance status (≥2), and tumors harboring a concurrent pathogenic KEAP1 mutation were shown to be associated with shorter median PFS and OS. Other variables such as age, presence of brain metastasis, the presence of STK11, and TP53 mutations did not have a significant impact on clinical outcomes.
conclusionIn this single-center, real-world, retrospective analysis, among the 38 patients with advanced NSCLC receiving KRAS G12C inhibitors, a never or light smoking history, poor performance status, and the presence of tumor pathogenic KEAP1 mutations were associated with worse clinical outcomes. Within the limitations of the study, clinicians should consider these variables when formulating treatment for KRAS G12C-mutant NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.